[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surfactant-deficiency-syndrome-neonatal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surfactant-deficiency-syndrome-neonatal":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,84,113,140,167,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100625698","video-vs-direct-laryngoscopy-for-less-invasive-surfactant-administration-100625698",false,"NCT07426016","Video vs. Direct Laryngoscopy for Less Invasive Surfactant Administration","Randomized Controlled Trial of Video-Laryngoscopy Intervention or Direct Laryngoscopy for Delivery of Less Invasive Surfactant Administration for Premature Infants","VID LISA","Inclusion Criteria:\n\n* Infants born ≤28 weeks GA successfully resuscitated in the delivery room (DR) and maintained on CPAP • Need for surfactant in the first 36 hours of life based on clinical assessment and\u002For meeting threshold per unit protocol\n\nExclusion Criteria:\n\n* Infants born ≥29 weeks GA or\n* Infants with known congenital anomalies or\n* Infants who are determined by the primary care team to receive comfort care only or\n* Infants who are intubated at any time prior to surfactant administration","ALL","0 Hours","3 Days",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Many preterm babies born between 22-28+6 weeks' estimated gestational age (EGA) need surfactant, a medicine that helps the lungs. The goal of the study is to compare the use of video-based visualization to direct visualization during a procedure called less invasive surfactant administration (LISA). The main questions the study aims to answer are: 1) does one method of visualization have a increased rate of giving the medicine successfully on the first attempt? 2) what benefits are there of each method?",[28,29],"Respiratory Distress Syndrome (Neonatal)","Surfactant Deficiency Syndrome Neonatal",[31,32,33],"less invasive surfactant","neonatal","video laryngoscopy","RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":35,"type":38},{"date":41,"type":22},"2028-11",{"name":43,"class":44},"University of Texas Southwestern Medical Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":45},"100613069","phase-4-duration-of-surfactant-administration-and-impact-on-stabilisation-of-vital-parameters-in-very-preterm-neonates-1-minutes-versus-5-minutes-100613069","NCT07261787","Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes","Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minute Versus 5 Minutes - a Prospective Randomised-controlled Phase IV Trial - A Randomised Clinical Trial on Influence of Duration of Surfactant Administration on Stabilisation of Routine Monitoring Parameters and Cerebral Tissue Oxygen Saturation Monitoring in Preterm Neonates \u003C 28 Weeks of Gestational Age","SurfStab I","Inclusion Criteria:\n\n* Preterm neonate \\\u003C28+0 weeks (gestational age up to 27 weeks and 6 days)\n* Indication of surfactant administration via the LISA method\n* Postnatal age \\\u003C 72 hours\n\nExclusion Criteria:\n\n* Invasive ventilation, indication of INSURE procedure\n* Severe pulmonary or cardiac malformation affecting oxygenation or congenital cerebral malformation\n* Preexisiting diagnose of any IVH \\> grade 2 or PVH.","0 Months","72 Hours",{"count":57,"type":22},76,[59],"PHASE4","Respiratory distress syndrome (RDS) is common in very preterm infants due to surfactant deficiency. Surfactant replacement therapy is lifesaving, and current guidelines recommend the less invasive surfactant administration (LISA) technique. However, the optimal duration of surfactant instillation during LISA has never been systematically evaluated. Rapid instillation may provoke transient hypoxia and bradycardia, while slower administration might improve physiological stability and cerebral oxygenation.\n\nThis randomised controlled trial investigates whether the duration of surfactant administration (1 minute versus 5 minutes) affects cerebral and systemic oxygen stability in extremely preterm neonates (\\\u003C 28 weeks).",[62,63,29,64,65,66],"Neonates and Preterm Infants","Infant Respiratory Distress Syndrome","Surfactant","Cerebral Oxygenation","Cerebral Oxygen Saturation",[68,69,70,71,72,73,74],"surfactant","surfactant administration","LISA","less-invasive surfactant administration","preterm neonates","cerebral oxygenation","near-infrared spectroscopy","2026-05-12",{"date":77,"type":38},"2026-05-14",{"date":79,"type":38},"2026-02-20",{"date":81,"type":22},"2028-12-01",{"name":83,"class":44},"Medical University of Graz",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":45},"100633104","demistify-the-impact-of-ventilator-pressure-levels-during-minimally-invasive-surfactant-therapy-on-lung-aeration-in-preterm-infants-100633104","NCT07522346","deMISTify: The Impact of Ventilator Pressure Levels During Minimally Invasive Surfactant Therapy on Lung Aeration in Preterm Infants","deMISTify: The Impact of CPAP Levels During Minimally Invasive Surfactant Therapy on Regional Patterns of Ventilation in Preterm Infants","deMISTify","Inclusion Criteria:\n\n* Born between 24 to 31+6 weeks' gestation, by best obstetric estimate\n* Admitted to a participating NICU\n* A parent\u002Fguardian who can provide informed consent\n* Receiving CPAP respiratory support\n* Planned to receive MIST by clinicians as standard clinical care\n* Clinically stable (as determined by clinical team)\n* Infant less than 72 hours of age\n* MIST can be administered within 90 min of allocating assigned interventional arm\n\nExclusion Criteria:\n\n* Receiving any form of respiratory support other than CPAP\n* Receiving more than 8 cmH2O PEEP via CPAP in the 4 hours prior to surfactant administration (except in the Delivery Room as part of resuscitation at birth)\n* The infant's clinical team has concern regarding clinical stability and tolerability of EIT\n* The infant's skin integrity will not tolerate the EIT belt and gel\n* Refusal of informed consent by their parent\u002Fguardian\u002Flegally acceptable representative\n* The infant does not have a parent\u002Fguardian who can provide informed consent.\n* Major congenital anomaly involving the cardiac, respiratory, gastrointestinal systems, or a known genetic syndrome or diagnosis that might affect respiratory course and outcomes\n* Severe pulmonary hypoplasia due to anhydramnios or oligohydramnios before 24 weeks in which the neonatal clinician anticipates that pulmonary hypoplasia related respiratory failure will be the major respiratory problem in early post-natal life\n* Suspected or confirmed air leak or pneumothorax\n* Previous treatment with surfactant or mechanical ventilation via an endotracheal tube\n* Urgent need for intubation and mechanical ventilation as determined by the treating clinician\n* Not receiving full active intensive care (i.e. palliative\u002Fcomfort care)","24 Weeks","32 Weeks",{"count":95,"type":22},36,[25],"Infants born preterm (before 36 weeks' gestation age) have immature lungs and struggle to breathe on their own. They are supported via respiratory machines like ventilators, as well as pharmaceutical aids like surfactant replacement therapy. Surfactant replacement therapy is an established therapy for the treatment of respiratory distress syndrome, which is a common illness in infants born preterm.\n\nSurfactant replacement therapy can be delivered to an infant's lungs a few ways, including via a small tube that is briefly placed down an infant's throat. This is considered the least invasive method currently available, and is becoming more popular. It is referred to as minimally invasive surfactant therapy (MIST). A baby can receive surfactant via MIST if they are receiving non-invasive respiratory support, like from a continuous positive airway pressure (CPAP) machine.\n\nDoctors and researchers are looking for simple ways to make MIST more effective. This clinical trial will investigate if briefly increasing the air pressure delivered by a CPAP machine before giving MIST therapy will make MIST more effective. This strategy is called a lung recruitment manoeuvre (LRM), because it opens up more of the lungs - 'recruits' them - to help with oxygenation. The CPAP setting that is briefly changed is called positive end expiratory pressure (PEEP) - it increases the amount of air left in the lungs at the end of a breath. This stops parts of the lung collapsing when exhaling, which commonly occurs in the lungs of infants born preterm as they are immature.\n\nThe goal of this clinical trial is to investigate if a LRM prior to MIST improves ventilation and lung aeration in preterm infants born 24-32 weeks' gestation. The main question it aims to answer is: How a LRM prior to MIST might impact patterns of ventilation and lung aeration in preterm infants, compared to no LRM prior to MIST.\n\nThe current standard of care is no LRM before MIST. Researchers will compare this current standard against a LRM before MIST to see if it potentially improves patterns of ventilation.\n\nParticipants will be randomly placed (by chance) to receive either no LRM before MIST (control) or a LRM before MIST (intervention). Participants will be randomised once their treating clinical team have decided to give MIST.",[29],[100,101,102],"Minimally Invasive Surfactant Therapy","Lung Recruitment Manoeuvre","Electrical Impedance Tomography","NOT_YET_RECRUITING","2026-04-08",{"date":106,"type":38},"2026-04-13",{"date":108,"type":22},"2026-04",{"date":110,"type":22},"2028-04",{"name":112,"class":44},"Murdoch Childrens Research Institute",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100558699","phase-4-pragmatic-evaluation-of-respiratory-distress-syndrome-treatment-in-africa-100558699","NCT06554522","Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa","Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa","Inclusion Criteria:\n\n* Birth weight between 750 and 2000 grams or gestational age between 24- and 35 weeks.\n* Silverman Anderson Score ≥5 before or after CPAP treatment.\n* Admitted to a study site within 24 hours of life.\n\nExclusion Criteria:\n\n* Major congenital or genetic anomalies.\n* Active pulmonary hemorrhage.\n* Major craniofacial anomalies that preclude the successful use of CPAP","1 Hour","24 Hours",{"count":123,"type":22},1512,[59],"The goal of this pragmatic clinical trial is to learn if the drug surfactant given by a less invasive technique works to treat respiratory distress in preterm infants in low- and middle-income African countries where invasive ventilators are unavailable. It will also learn about the safety of the less invasive surfactant administration (LISA) technique. The main questions it aims to answer are:\n\nDoes surfactant given by a less invasive surfactant administration technique improve survival in preterm infants in low- and middle-income countries? What medical problems do participants have when receiving surfactant given by the less invasive surfactant administration technique?\n\nResearchers will implement the less invasive surfactant administration technique and see if it works to treat respiratory distress in preterm infants compared to preterm who did not receive surfactant.\n\nParticipants with respiratory distress who are being treated with continuous positive airway pressure and caffeine citrate will:\n\nReceive surfactant replacement therapy by the less invasive surfactant administration technique.\n\nBe monitored for complications Be followed throughout their hospitalization to determine their survival rate.",[127,128,29,129],"Respiratory Distress Syndrome in Premature Infant","RDS of Prematurity","Premature Birth","2026-03-23",{"date":132,"type":38},"2026-03-27",{"date":134,"type":38},"2025-01-01",{"date":136,"type":22},"2027-12-30",{"name":138,"class":44},"Indiana University",8,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100396704","surfactant-administration-by-insure-or-thin-catheter-100396704","NCT04445571","Surfactant Administration by Insure or Thin Catheter","SAINT","Inclusion Criteria:\n\n* Infants born before 32 completed weeks of gestation on CPAP, with clinical and radiological signs of RDS and need for surfactant treatment.\n\nExclusion Criteria:\n\n* Infants requiring surfactant as part of delivery room resuscitation are not eligible.\n\nInfants will be excluded from the final analysis if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation, including: congenital diaphragmatic hernia; tracheo-oesophageal fistula or cyanotic heart disease.","2 Days",{"count":149,"type":22},160,[25],"This trial evaluates the efficacy and safety of surfactant administration with thin catheter technique together with analgesic premedication in comparison with the established INSURE-strategy. It will provide valuable knowledge to improve clinical methodology and enhance lung protective treatment strategies for preterm infants.",[128,29,153],"Analgesia",[155,156,157],"LISA (Less invasive surfactant administration)","INSURE","CPAP","2025-06-26",{"date":160,"type":38},"2025-07-01",{"date":162,"type":38},"2021-05-21",{"date":164,"type":22},"2026-12-31",{"name":166,"class":44},"Karolinska Institutet",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100548477","less-invasive-surfactant-administration-in-late-preterm-or-early-term-born-infants-100548477","NCT06421506","Less Invasive Surfactant Administration in Late Preterm or Early Term Born Infants","Does Less Invasive Surfactant Administration (LISA) During High-flow Nasal Cannula Oxygen Treatment Reduces the Need for Invasive Ventilation in Late Preterm and Term Born Infants With Respiratory Distress?","Inclusion Criteria:\n\n* Infants born at 34+0 to 38+6 weeks of gestation, requiring resuscitation at birth, but who achieve regular spontaneous breathing and have a heart rate over 100 beats per minute while receiving non-invasive support.\n* Infants enrolled in the Surfon trial, born at 34+0 to 38+6 weeks of gestation, who are less than or equal to 24 hours old and exhibit signs of respiratory distress, defined as an FiO2 greater or equal to 0.30 but less than 0.45 needed to maintain an SpO2 greater than or equal to 92% or a clinically significant work of breathing regardless of the FiO2 and a clinical decision to provide non-invasive respiratory support.\n\nExclusion Criteria:\n\n* Infants requiring intubation at birth\n* Infants with severe congenital anomalies.","34 Weeks","38 Weeks",{"count":177,"type":22},245,[25],"The aim of this study is to see if giving less invasive surfactant administration (LISA) during high-flow nasal cannula (HFNC) oxygen treatment reduces the need for invasive ventilation in babies with breathing problems born 2-6 weeks early.\n\nLess invasive surfactant administration is where surfactant (a naturally produced substance which helps open up the tiny air sacs in the lungs making it easier for babies to breathe) is given into the lungs by putting a small tube into the windpipe through the mouth whilst the baby is awake. The surfactant is given slowly and breathed in.\n\nHigh flow nasal cannula is a form of non-invasive support where a machine delivers warmed, moist oxygen and air through short tubes in the nose.\n\nThe investigators will be assessing whether a lower percentage of neonates need invasive ventilation within 72 hrs from birth when they have had LISA during HFNC treatment, compared to when they don't receive this treatment.\n\nThe investigators will also be looking at the length of neonatal unit stay and the cost of the stay. The investigators will also be measuring the lung function of the babies before and after they receive LISA.",[181,182,29],"Respiratory Distress Syndrome","Preterm Pregnancy","2024-05-21",{"date":185,"type":38},"2024-05-22",{"date":187,"type":22},"2024-05",{"date":189,"type":22},"2026-09",{"name":191,"class":44},"King's College Hospital NHS Trust",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":45},"100342205","phase-4-premedication-for-less-invasive-surfactant-administration-100342205","NCT03735563","Premedication for Less Invasive Surfactant Administration","LISA-Med","Inclusion Criteria:\n\n* Gestational age at birth ≥26 weeks\n* Respiratory insufficiency managed with non-invasive respiratory support (nasal continuous positive airway pressure or high-flow)\n* Requirement for oxygen to maintain oxygen saturation in the target range and need for surfactant treatment (according to clinician's assessment)\n* If further doses of surfactant are needed, patient can be re-randomized\n\nExclusion Criteria:\n\n* Severe RDS with high oxygen requirements, severe respiratory acidosis and\u002For widespread atelectasis radiologically, such that ongoing ventilator support will be necessary after surfactant therapy (intubation in preferable to LISA if FiO2 \\>40% at GA \\\u003C28 weeks and \\>60% at GA ≥28 weeks)\n* Maxillo-facial, tracheal or known pulmonary malformations\n* Any known chromosomal abnormality or severe malformation\n* An alternative cause for respiratory distress (e.g. congenital pneumonia or pulmonary hypoplasia)",{"count":200,"type":22},40,[59],"Early respiratory management of preterm infants immediately after birth should be as gentle as possible. With this so-called developmental approach, unnecessary invasive methods can be avoided or at least postponed. This kind of \"soft landing\" allows cardiorespiratory transition with fewer adverse outcomes. Less invasive surfactant administration (LISA) is a technique that involves delivery of surfactant to a spontaneously breathing infant through a thin catheter. This technique minimizes the risk for neonatal lung injury caused by positive pressure ventilation. LISA is nowadays widely used in neonatal intensive care units (NICU). Although less invasive, newborns exposed to this procedure need premedication prior the procedure. There is no consensus, which drug would be the optimal premedication for LISA and the research on this topic is lacking. An ideal premedication would treat the procedural pain without suppressing the infant's own breathing. The sedation and analgesia should start fast but the effect should be short-acting with as few adverse effects as possible. The aim of this randomized, controlled trial (RCT) is to evaluate the feasibility, efficacy and safety of LISA protocol with the premedication of either ketamine or fentanyl by investigating whether one or the other is associated with lower rate of adverse events, hence would be preferred choice for premedication protocol.",[29],[205,206],"less invasive surfactant administration","premedication","2023-06-02",{"date":209,"type":38},"2023-06-05",{"date":211,"type":38},"2019-02-11",{"date":213,"type":22},"2026-10-31",{"name":215,"class":44},"University of Oulu"]